Oncology

Trastuzumab: Mechanism of Action, Uses, Dosing, Side Effects, HER2 Testing and Clinical Guide

By Dr. Ahmed Mujtaba • Published: September 11, 2026 • 13 min read

1. The Underlying Mechanism and Clinical Rationale

Trastuzumab is one of the landmark targeted therapies in modern oncology. This humanized monoclonal antibody specifically targets human epidermal growth factor receptor 2 (HER2/ERBB2) and has transformed the treatment of HER2-positive breast cancer and HER2-positive gastric and gastroesophageal junction (GEJ) cancers.

For students remember:

<blockquote>Trastuzumab → HER2 targeting → HER2 signaling inhibition + ADCC → inhibition of tumor growth</blockquote>

For healthcare professionals, however, trastuzumab involves much more than its mechanism of action. Correct HER2 testing, patient selection, treatment setting, dosing, cardiac monitoring, combination therapy, resistance and treatment sequencing are all clinically important.

What Is Trastuzumab:

Trastuzumab is a humanized IgG1 monoclonal antibody directed against HER2.

<ul><li>Generic name: Trastuzumab</li><li>Drug class: Anti-HER2 monoclonal antibody</li><li>Antibody: Humanized IgG1</li><li>Target: HER2/ERBB2</li><li>Major uses: HER2-positive breast cancer and selected HER2-positive gastric/GEJ cancers</li><li>Major toxicity: Cardiac dysfunction/cardiomyopathy</li><li>Important monitoring: Left ventricular function, particularly LVEF</li><li>Administration: IV; selected formulations allow subcutaneous administration</li></ul>

Trastuzumab only provides meaningful benefit when the tumor has the appropriate HER2 biology. Therefore, HER2 testing is central to treatment selection.

What is HER-2 ?

HER2, also known as ERBB2, is a transmembrane receptor tyrosine kinase belonging to the HER/ErbB receptor family. The family includes:

These receptors participate in signaling pathways controlling:

<ul><li>Cell growth</li><li>Proliferation</li><li>Survival</li><li>Differentiation</li><li>Migration</li></ul>

<blockquote>In some cancers, particularly breast cancer, the HER2 gene may be amplified or the HER2 protein may be overexpressed. This can lead to excessive growth and survival signaling. Therefore, HER2 can function as both a biological driver of cancer and a therapeutic target.</blockquote>

What Is HER2-Positive Cancer?

In breast cancer, HER2 status is generally determined using validated immunohistochemistry (IHC) and/or in situ hybridization (ISH) testing.

IHC evaluates HER2 protein expression and is commonly reported as:

A key clinical concept is IHC 3+ ( Generally considered HER2-positive )

IHC 2+ ( Equivocal and generally requires appropriate ISH assessment )

IHC 0 or 1+  ( Does not meet the traditional definition of HER2-positive breast cancer for conventional trastuzumab therapy )

ASCO/CAP continues to emphasize standardized HER2 testing to identify tumors with HER2 protein overexpression and/or gene amplification that may benefit from conventional HER2-directed therapies.

<blockquote>HER2-low does not simply mean HER2-positive.</blockquote>

HER2-low expression has become clinically relevant for certain newer antibody-drug conjugates, particularly trastuzumab deruxtecan (T-DXd), but it should not automatically be interpreted as an indication for conventional trastuzumab.

How Does Trastuzumab Works:

Trastuzumab has two major concepts that students should remember:

1) HER-2 signaling inhibition:

Trastuzumab binds to the extracellular region of HER2 and interferes with HER2-mediated signaling. This reduces signaling involved in cancer-cell growth and survival.

Important downstream pathways include:

2) ADCC:

Trastuzumab is an IgG1 antibody. After binding to HER2 on a tumor cell, its Fc region can interact with Fc receptors on immune effector cells, particularly natural killer (NK) cells. The NK cell recognizes the antibody-coated cancer cell and contributes to its destruction. This is called ADCC — Antibody-Dependent Cellular Cytotoxicity.

The simplest way to remember the mechanism is:

<blockquote>Trastuzumab binds HER2 → inhibits signaling → recruits immune-mediated tumor-cell killing.</blockquote>

Trastuzumab vs Pertuzumab: Why Are They Different?

This is a high-yield pharmacology and examination point.

Both drugs target HER2, but they bind different regions of the receptor.

A) TRASTUZUMAB: Particularly binds to Domain IV

B)  PERTUZUMAB: Binds Domain II and interferes particularly with HER2-HER3 dimerization.

<blockquote>Trastuzumab + Pertuzumab = complementary/dual HER2 blockade</blockquote>

This is why the two antibodies can be combined in appropriate HER2-positive breast cancer treatment settings.

Clinical Uses of Trastuzumab:

The exact approved indications depend on the product, formulation and regulatory authority.

Major established applications include:

HER2-positive breast cancer:

Trastuzumab can be incorporated into treatment for:

<ul><li>Early breast cancer</li><li>Locally advanced disease</li><li>Metastatic breast cancer</li></ul>

Depending on disease characteristics, it may be used in:

<ul><li>Neoadjuvant treatment</li><li>Adjuvant treatment</li><li>Metastatic treatment</li></ul>

HER2-positive gastric and GEJ cancer:

Trastuzumab also has an established role in selected patients with:

<ul><li>HER2-positive metastatic gastric adenocarcinoma</li><li>HER2-positive gastroesophageal junction adenocarcinoma</li></ul>

Clinical Pearl: In advanced gastric cancer, HER2 testing is important for identifying appropriate candidates for HER2-directed treatment.

2. Pharmacological Dynamics and Patient-Specific Factors

Trastuzumab in Early HER2-Positive Breast Cancer:

Trastuzumab dramatically changed outcomes in HER2-positive early breast cancer.

For appropriate patients, HER2-directed therapy may be incorporated into neoadjuvant and/or adjuvant treatment.

<blockquote>For higher-risk stage II–III disease, contemporary treatment commonly incorporates trastuzumab with chemotherapy and, where appropriate, pertuzumab.</blockquote>

The objectives include:

<ul><li>Reducing tumor burden</li><li>Increasing pathological response</li><li>Treating micrometastatic disease</li><li>Reducing recurrence risk</li><li>Improving long-term outcomes</li></ul>

<blockquote>The HERA trial demonstrated that one year of adjuvant trastuzumab significantly improved disease-free survival compared with observation in HER2-positive early breast cancer.</blockquote>

What If Residual Disease Remains After Neoadjuvant Therapy?

This is an important professional-level concept.

Consider:

<blockquote>Neoadjuvant chemotherapy + HER2-directed therapy → surgery → residual invasive HER2-positive disease</blockquote>

In this situation, treatment may change from trastuzumab to trastuzumab emtansine (T-DM1) in appropriate patients.

The landmark KATHERINE trial compared adjuvant T-DM1 with trastuzumab in patients with residual invasive HER2-positive breast cancer after neoadjuvant treatment.

At the primary analysis, T-DM1 reduced the risk of invasive disease recurrence or death by approximately 50% compared with trastuzumab. Three-year invasive disease-free survival was 88.3% with T-DM1 versus 77.0% with trastuzumab.

Longer-term follow-up continued to demonstrate benefit, including improved overall survival.

Therefore:

<blockquote>Residual invasive HER2-positive disease after neoadjuvant therapy is a major treatment decision point.</blockquote>

<ol><li>Trastuzumab in Metastatic HER2-Positive Breast Cancer</li></ol>

HER2-directed therapy remains a major component of metastatic HER2-positive breast cancer treatment. Treatment sequencing has evolved substantially.

For appropriate patients, ASCO recommends:

FIRST LINE:

<blockquote>Trastuzumab + Pertuzumab + Taxane</blockquote>

This recommendation is supported by high-quality evidence.

SECOND LINE:

<blockquote>For patients who progress after first-line HER2-directed therapy and have not previously received it, trastuzumab deruxtecan (T-DXd) is recommended by ASCO as second-line treatment.</blockquote>

Therefore, it is no longer accurate to describe T-DM1 as the universal second-line standard in modern metastatic HER2-positive breast cancer.

<blockquote>Later-line treatment may include different HER2-directed approaches depending on previous therapy, disease characteristics, CNS involvement, toxicity, access and local guidelines.</blockquote>

Trastuzumab Dosing:

Dosing depends on:

<ul><li>Disease setting</li><li>Formulation</li><li>Route</li><li>Treatment schedule</li><li>Combination regimen</li></ul>

A commonly used three-weekly IV breast cancer regimen is:

<blockquote>Loading dose 8mg/kg IV Followed by 6mg/kg IV</blockquote>

A weekly IV regimen may also be used in selected protocols:

<blockquote>Loading dose: 4mg/kg Followed by: 2mg/kg</blockquote>

The exact dose and schedule should always be verified against the specific product information and institutional oncology protocol.

Subcutaneous Trastuzumab:

Some trastuzumab formulations allow subcutaneous administration.

The major practical advantage is reduced administration time and potentially less infusion-chair utilization.

However, IV and subcutaneous formulations are not automatically interchangeable.

The formulation specific:

<ul><li>Dose</li><li>Administration method</li><li>Eligibility</li><li>Preparation</li><li>Monitoring</li></ul>

must be checked before administration.

<blockquote>The EMA recognizes both IV and subcutaneous Herceptin formulations.</blockquote>

Trastuzumab Biosililars:

Multiple trastuzumab biosimilars have been approved internationally.

<blockquote><ul><li>Kanjinti</li></ul><ul><li>Ogivri</li></ul><ul><li>Trazimera</li></ul><ul><li>Herzuma</li></ul><ul><li>Zercepac</li></ul></blockquote>

A biosimilar is not simply a generic copy of a biologic.

It is a biologic product demonstrated to be highly similar to the reference product, with no clinically meaningful differences in relevant quality, efficacy and safety within the regulatory framework.

Biosimilars are clinically important because they may improve:

<ul><li>Patient access</li><li>Availability</li><li>Healthcare affordability</li></ul>

<div>Major Adverse Effects:</div>

The most important toxicities to remember are:

1. CARDIAC DYSFUNCTION:

This is the major clinical safety concern.

Possible manifestations include:

<ul><li>Reduced LVEF</li><li>Asymptomatic cardiac dysfunction</li><li>Cardiomyopathy</li><li>Symptomatic heart failure</li></ul>

The risk is particularly important in patients with previous or concurrent exposure to cardiotoxic therapy, especially anthracyclines.

2. INFUSION-RELATED REACTIONS:

<ul><li>Fever</li><li>Chills</li><li>Rigors</li><li>Dyspnea</li><li>Hypotension</li><li>Nausea</li><li>Headache</li></ul>

Serious reactions can occur, particularly during early administrations.

3. PULMONARY TOXICITY:

Rare but serious pulmonary complications can occur, including severe respiratory reactions and pneumonitis.

4. EMBRYO-FETAL TOXICITY:

HER2-directed therapy can cause fetal harm. Pregnancy considerations are therefore important before and during treatment.

OTHER ADVERSE EFFECTS:

Depending on the treatment combination, patients may also experience:

<ul><li>Fatigue</li><li>Diarrhea</li><li>Nausea</li><li>Infections</li><li>Neutropenia</li><li>Headache</li></ul>

Some of these effects may be primarily related to the accompanying chemotherapy rather than trastuzumab itself.

Clinical Pearl: The EMA specifically identifies cardiac, pulmonary, infusion-related and other serious toxicities as important safety considerations.

High-Yield Point: Monitor therapeutic response with standardized laboratory benchmarks.
Risk Mitigation: Implement routine medication reconciliation to eliminate adverse drug events.
Patient Empowerment: Communicate clear, jargon-free instructions to enhance therapy compliance.

3. Practical Clinical Applications and Safety Guidelines

<div>Trastuzumab Cardiotoxicity:For oncology pharmacists and other healthcare professionals, this is one of the most important clinical considerations.Trastuzumab-associated cardiac dysfunction may present as:<blockquote>Asymptomatic LVEF reduction → symptomatic heart failure</blockquote>Risk may be increased by:A. Previous anthracycline exposureB. Older ageC. HypertensionD. Pre-existing cardiovascular diseaseE. Reduced base line LVEFWhy Does Trastuzumab Affect the Heart?HER2 signaling is not only relevant to cancer cells. HER2-related signaling also contributes to cardiomyocyte survival and stress responses. Blocking this pathway can reduce protective signaling in cardiac tissue.<blockquote>HER2 blockade → reduced cardioprotective signaling → increased susceptibility to cardiac dysfunction</blockquote> </div>

This differs mechanistically from the classic cumulative myocardial injury associated with anthracyclines.

That distinction is clinically important because trastuzumab-related cardiac dysfunction may be potentially reversible in many patients when recognized and managed appropriately.

Cardiac Monitoring:

Before starting trastuzumab, cardiac function should be assessed.

A. Echocardiography: Used to assess LVEF and other cardiac parameters.

B. MUGA: May be used in selected situations when appropriate.

Clinical assessment should consider:

<ul><li>Baseline LVEF</li><li>History of heart failure</li><li>Ischemic heart disease</li><li>Hypertension</li><li>Previous cardiotoxic therapy</li><li>Other cardiovascular risk factors</li></ul>

During therapy, patients generally require serial cardiac assessment.

The key clinical association is:

<blockquote>Trastuzumab → Cardiac dysfunction → LVEF monitoring</blockquote>

Trastuzumab and Anthracyclines:

One of the most important safety principles is:

<blockquote>Trastuzumab + anthracycline exposure = increased cardiac risk</blockquote>

Important anthracyclines include:

A. Doxorubicin

B. Epirubicin

Because both treatment approaches can affect cardiac function, oncology regimens are carefully designed to balance efficacy and cardiac safety.

This is one reason non-anthracycline chemotherapy backbones may be considered in selected HER2-positive patients.

Trastuzumab Resistance:

Not every HER2-positive tumor responds permanently to trastuzumab.

Resistance can be:

A) Primary Resistance: The tumor does not respond adequately from the beginning.

B) Acquired Resistance: The tumor initially responds but later progresses. Potential mechanisms include:

<ul><li>Altered HER2 signaling</li><li>PI3K/AKT pathway activation</li><li>PI3K pathway alterations</li><li>PTEN pathway changes</li><li>HER2 receptor alterations</li><li>HER2 heterogeneity</li><li>Alternative growth pathways</li><li>Reduced immune-mediated activity</li></ul>

This explains why modern oncology uses multiple HER2-directed strategies rather than relying on a single antibody indefinitely.

Trastuzumab and CNS Metastases:

HER2-positive breast cancer has a clinically important risk of brain metastases.

Although trastuzumab has dramatically improved systemic disease control, CNS disease remains challenging because antibody penetration into the CNS is limited.

Consequently, modern HER2-positive breast cancer treatment may involve HER2-directed agents with demonstrated intracranial activity when brain metastases are present.

Treatment selection depends on:

<ul><li>Previous HER2-directed therapy</li><li>CNS disease status</li><li>Symptoms</li><li>Extracranial disease</li><li>Previous radiation</li><li>Drug availability</li><li>Local guidelines</li></ul>

Therefore, CNS progression should not simply be managed by continuing the same systemic regimen without reassessment.

Final Takeaway:

Trastuzumab is a landmark example of precision oncology. It works by targeting HER2, reducing HER2-driven signaling and helping immune cells destroy antibody-coated tumor cells through ADCC. But effective trastuzumab therapy requires more than knowing its mechanism.

Clinicians must understand:

<blockquote>HER2 testing → patient selection → appropriate regimen → dosing → cardiac monitoring → toxicity management → resistance → treatment sequencing.</blockquote>

Always verify the current product information and applicable oncology guidelines before making treatment decisions because indications, dosing, formulations and treatment sequencing can vary by country, product and clinical setting.

Key Clinical Takeaways

Trastuzumab: Mechanism of Action, Uses, Dosing, Side Effects, HER2 Testing and Clinical Guide requires thorough evaluation of biological mechanisms and individualized patient risk factors.
Therapeutic monitoring and proactive adverse effect mitigation are essential for optimizing treatment outcomes.
Interprofessional collaboration between physicians, clinical pharmacists, and nursing staff enhances patient safety.
Educating patients with simplified, transparent healthcare knowledge improves long-term medication compliance.

Frequently Asked Questions

Why is understanding Trastuzumab: Mechanism of Action, Uses, Dosing, Side Effects, HER2 Testing and Clinical Guide critical for healthcare providers and patients?

Clear comprehension of pharmacological pathways and clinical guidelines enables safer prescribing, minimizes preventable adverse drug events, and ensures patients understand the purpose and safety of their therapy.

What are the primary clinical monitoring parameters for this therapy?

Clinicians should assess baseline renal and hepatic function, evaluate potential cytochrome P450 drug interactions, and schedule regular follow-ups to track symptom resolution and laboratory biomarkers.

How does Dr. Ahmed Mujtaba approach patient education for this topic?

By breaking down complex molecular mechanisms into intuitive visual analogies and clear clinical pearls, patients gain confidence and active agency in their healthcare journey.

Medical Disclaimer: This article is authored strictly for healthcare educational, informational, and academic purposes. It does not constitute individual clinical advice, diagnosis, or treatment. Always consult a qualified physician or pharmacist regarding prescription medications.

What Happens If You Suddenly Stop Your Blood Pressure Medicine?

8 min read • August 26, 2026

Irinotecan: From SN-38 to Cancer Cell Death — Easy Explanation

13 min read • August 29, 2026

Dapsone-Induced Methemoglobinemia: Chocolate-Brown Blood, Mechanism, Symptoms, Diagnosis and Treatment

18 min read • September 5, 2026